Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00799773 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)
A Phase 3 study, sponsored by Carelon Research.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3
- Enrollment target
NCT00799773: Clinical Trial Phase 3 study, sponsored by Carelon Research.
NCT00799773 is a Phase 3 study that was terminated before completion, run by Carelon Research. The registered enrollment target is 3 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00799773, a Phase 3 study, was terminated before completion, sponsored by Carelon Research.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3 participants
- Enrollment target
Study Summary
Thrombotic thrombocytopenic purpura (TTP) is a rare disorder that causes blood clots to form in blood vessels. The main treatment for TTP is plasma exchange, in which affected patients receive transfusions of plasma, the liquid part of blood, from healthy donors. This study will examine the effectiveness of an antibody, rituximab, in combination with plasma exchange, at improving the immune response in people with TTP and decreasing the recurrence of TTP.
Interventions
- DRUG Rituximab
- PROCEDURE Plasma exchange
- DRUG Corticosteroids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Why NCT00799773 stopped before completion
NCT00799773 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 3 interventions - of which Rituximab is the first listed.
NCT00799773 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00799773 about?
NCT00799773 is a clinical study titled "Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)". Thrombotic thrombocytopenic purpura (TTP) is a rare disorder that causes blood clots to form in blood vessels. The main treatment for TTP is plasma exchange, in which affected patients receive transfusions of plasma, the liquid part of blood, from healthy donors. This study will examine the effectiv...
What is the current status of trial NCT00799773?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3 participants. The study started on 2009-04. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00799773?
The interventions under investigation include: Rituximab (DRUG), Plasma exchange (PROCEDURE), Corticosteroids (DRUG).
Who is sponsoring clinical trial NCT00799773?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00799773's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia